17 research outputs found
Genetic variations in microRNA-binding sites of solute carrier transporter genes as predictors of clinical outcome in colorectal cancer
One of the principal mechanisms of chemotherapy resistance in highly frequent solid tumors, such as colorectal cancer (CRC), is the decreased activity of drug transport into tumor cells due to low expression of important membrane proteins, such as solute carrier (SLC) transporters. Sequence complementarity is a major determinant for target gene recognition by microRNAs (miRNAs). Single-nucleotide polymorphisms (SNPs) in target sequences transcribed into messenger RNA may therefore alter miRNA binding to these regions by either creating a new site or destroying an existing one. miRSNPs may explain the modulation of expression levels in association with increased/decreased susceptibility to common diseases as well as in chemoresistance and the consequent inter-individual variability in drug response. In the present study, we investigated whether miRSNPs in SLC transporter genes may modulate CRC susceptibility and patient's survival. Using an in silico approach for functional predictions, we analyzed 26 miRSNPs in 9 SLC genes in a cohort of 1368 CRC cases and 698 controls from the Czech Republic. After correcting for multiple tests, we found several miRSNPs significantly associated with patient's survival. SNPs in SLCO3A1, SLC22A2 and SLC22A3 genes were defined as prognostic factors in the classification and regression tree analysis. In contrast, we did not observe any significant association between miRSNPs and CRC risk. To the best of our knowledge, this is the first study investigating miRSNPs potentially affecting miRNA binding to SLC transporter genes and their impact on CRC susceptibility or patient's prognosis
Recommended from our members
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer
Highly Cytotoxic Palladium(II) Pincer Complexes Based on Picolinylamides Functionalized with Amino Acids Bearing Ancillary <i>S</i>‑Donor Groups
The reactions of
picolinyl and 4-chloropicolinyl chlorides with methyl esters of <i>S</i>-methyl-l-cysteine, l- and d-methionine, and l-histidine afforded a series of functionalized
carboxamides, which readily formed pincer-type complexes upon interaction
with PdCl<sub>2</sub>(NCPh)<sub>2</sub> in solution under mild conditions.
The direct cyclopalladation of the ligands derived was also accomplished
in the solid phase, in particular, mechanochemically, although it
was complicated by the partial deactivation of the starting amides.
The resulting complexes with 5,5- and 5,6-membered fused metallocycles
were fully characterized by IR and NMR spectroscopy, including variable-temperature
and 2D-NMR studies. In the case of some cysteine- and methionine-based
derivatives, the realization of κ<sup>3</sup>-<i>N,N,S-</i>coordination was supported by X-ray diffraction. The cytotoxic effects
of these complexes were examined on HCT116, MCF7, and PC3 human cancer
cell lines as well as HEK293 as a representative of normal cells.
The comparative studies allowed us to determine that the presence
of the sulfide ancillary donor group is crucial for cytotoxic activity
of this type of PdÂ(II) complexes. The main structure–activity
relationships and the most promising palladocycles were outlined.
The additional studies by gel electrophoresis revealed that 4-chloropicolinyl
derivatives, despite the nature of an amino acid, can bind with DNA
and inhibit topoisomerase I activity
Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer.
BACKGROUND AND AIMS: The gut microbiota is implicated in the pathogenesis of colorectal cancer (CRC). We aimed to map the CRC mucosal microbiota and metabolome and define the influence of the tumoral microbiota on oncological outcomes. METHODS: A multicentre, prospective observational study was conducted of CRC patients undergoing primary surgical resection in the UK (n = 74) and Czech Republic (n = 61). Analysis was performed using metataxonomics, ultra-performance liquid chromatography-mass spectrometry (UPLC-MS), targeted bacterial qPCR and tumour exome sequencing. Hierarchical clustering accounting for clinical and oncological covariates was performed to identify clusters of bacteria and metabolites linked to CRC. Cox proportional hazards regression was used to ascertain clusters associated with disease-free survival over median follow-up of 50 months. RESULTS: Thirteen mucosal microbiota clusters were identified, of which five were significantly different between tumour and paired normal mucosa. Cluster 7, containing the pathobionts Fusobacterium nucleatum and Granulicatella adiacens, was strongly associated with CRC (PFDR = 0.0002). Additionally, tumoral dominance of cluster 7 independently predicted favourable disease-free survival (adjusted p = 0.031). Cluster 1, containing Faecalibacterium prausnitzii and Ruminococcus gnavus, was negatively associated with cancer (PFDR = 0.0009), and abundance was independently predictive of worse disease-free survival (adjusted p = 0.0009). UPLC-MS analysis revealed two major metabolic (Met) clusters. Met 1, composed of medium chain (MCFA), long-chain (LCFA) and very long-chain (VLCFA) fatty acid species, ceramides and lysophospholipids, was negatively associated with CRC (PFDR = 2.61 × 10-11); Met 2, composed of phosphatidylcholine species, nucleosides and amino acids, was strongly associated with CRC (PFDR = 1.30 × 10-12), but metabolite clusters were not associated with disease-free survival (p = 0.358). An association was identified between Met 1 and DNA mismatch-repair deficiency (p = 0.005). FBXW7 mutations were only found in cancers predominant in microbiota cluster 7. CONCLUSIONS: Networks of pathobionts in the tumour mucosal niche are associated with tumour mutation and metabolic subtypes and predict favourable outcome following CRC resection. Video Abstract
Additional file 1: Table S1. of Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma
Lists TaqMan Gene Expression Assays used in the study. Table S2 shows sequence of primers and PCR conditions used for promoter CpG methylation profiling. Table S3 shows results of stage-adjusted Cox regression of associations between transcript levels and DFI of colorectal cancer patients from the combined testing and validation I sets. Figure S1 depicts 5-Fluorouracil pathway gene expression levels in the studied sets of colorectal cancer patients. Figure S2 shows results of analysis of associations between transcript levels and disease-free survival of colorectal cancer patients from the validation set I. Figure S3 shows results of analysis of associations between transcript levels and disease-free survival of colorectal cancer patients from the testing set. Figure S4 shows results of analysis of associations between transcript levels and disease-free survival of colorectal cancer patients from the combined testing and validation I set. Figure S5 shows results of analysis of associations between transcript levels and disease-free survival of 5-fluorouracil-treated colorectal cancer patients from the combined testing and validation I set. Figure S6 shows results of analysis of associations between transcript levels and disease-free survival of untreated colorectal cancer patients from the validation I set. Figure S7 shows results of analysis of associations between UPB1 methylation levels and disease-free survival of colorectal cancer patients. Figure S8 shows analysis of association of RRM2 expression with disease-free survival of colorectal cancer patients based on publicly available GEO database. Figure S9 shows analysis of methylation profiles of 5-FU pathway genes in human colorectal tumor (red boxes) and mucosa (green boxes) tissues from publicly available MethHC database. (DOC 1916 kb